UNSPSC 51191954: Thiamine propyl disulfide

This classification denotes a b vitamin with the molecular formula C15H24N4O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UI32MM3XE3, chemically known as n-((4-amino-2-methyl-5-pyrimidinyl)methyl)-n-(4-hydroxy-1-methyl-2-(propyldithio)-1-butenyl)formamide, but more generally known as thiamine propyl disulfide, which bears US NIH Compound Identifier 4963. European Medicines Agency schedules thiamine propyl disulfide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10969MIG.

Most nations, for tariff purposes, schedule thiamine propyl disulfide under HS 29362200. SMILES: CCCSS/C(=C(\C)/N(CC1CNC(NC1N)C)C=O)/CCO.

UNSPSC 51191954 Thiamine propyl disulfide is a Commodity code that encompasses specialized chemical and pharmaceutical ingredients used in water treatment, healthcare facility operations, and multi-source pharmaceutical distribution across state and local government systems. Recent solicitations show state and local governments procuring both raw treatment chemicals and finished pharmaceutical products under this code's nominal scope, though the actual buying activity spans a broader range of chemical and pharmaceutical commodities than the specific ingredient name suggests. Issuing bodies include municipal utilities—particularly water pollution control facilities—and cooperative purchasing alliances administered by state procurement offices. The City of Meriden's Water Pollution Control Facility and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represent the issuing-body mix, with MMCAP serving multiple state and local government facilities across participating jurisdictions including Oregon.

Recent activity centers on Connecticut and Minnesota. The City of Meriden posted an IFB for sodium bisulfite chemical supply under solicitation B02715 with a due date of July 29, 2026, requiring General Liability coverage of $1,000,000 to $2,000,000 and performance and payment bonds. MMCAP issued an RFP (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products, with proposals due March 26, 2026, and awarded vendors to be effective July 1, 2026. The MMCAP RFP requires vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with pricing evaluated at 75 percent weight, compliance and administrative requirements at 20 percent, and fixed pricing at 10 percent. Vendors must maintain commercial general liability coverage of $5,000,000 per occurrence, certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and accept a 3 percent administrative fee on all contract purchases.